New course!
This session explores how pharmaceutical and biotechnology products move from scientific innovation to payer-funded therapy.
Key themes include:
• health technology assessment logic
• value proposition development
• comparator strategy
• cost-effectiveness and economic evidence
• translating clinical data into payer language
• using Australian evidence to shape global value narratives.
Learning Outcomes
• understand the economic logic behind healthcare adoption
• structure a value proposition that aligns with HTA decision-making
• translate clinical evidence into payer-relevant arguments
• identify the most suitable first market for adoption
• use Australian evidence to support international market access strategies
• understand how different health systems reward different forms of value.
Who should attend:
• professionals working in pharmaceutical, biotechnology and medical technology companies
• market access and health economics specialists
• clinical development and evidence generation teams
• commercial strategy and innovation leaders
• researchers interested in the translation of medical innovation into healthcare systems
Steven Haken is Managing Director of Odelle Technology, an international consultancy specialising in reimbursement strategy, health economics, and the adoption of medical innovation within healthcare systems.
With more than two decades of experience working with pharmaceutical, biotechnology, diagnostic and medical technology companies across Europe, the United Kingdom and internationally, he advises organisations on how innovations move from regulatory approval to real-world adoption within national health systems.
ARCS member - $45 +GST
Non-member - $90 +GST
.png){kind=logo}
.png)
%20(2).jpg)
